Therapeutic Potential of Targeting Epigenetic Factors HIF-1a and KDM3A in Ovarian Cancer and PCOS

Abstract

Ovarian cancer and polycystic ovary syndrome (PCOS) are significant health concerns for women, posing challenges in terms of treatment and prognosis. Hypoxia-inducible factor 1 alpha (HIF-1a) and lysine demethylase 3A (KDM3A) have emerged as promising therapeutic targets for both conditions due to their involvement in critical cellular processes. This article explores the therapeutic potential of targeting HIF-1a and KDM3A in ovarian cancer and PCOS, investigating their molecular mechanisms in disease progression, including angiogenesis, cell proliferation, and metabolic dysregulation. Recent preclinical and clinical studies evaluating the effectiveness of HIF-1a and KDM3A inhibitors are discussed, emphasizing their potential as innovative therapeutic strategies. These findings highlight the importance of understanding the complex interplay between HIF-1a, KDM3A, and the pathogenesis of ovarian cancer and PCOS, ultimately facilitating the development of targeted therapies.